Loading
Turned the thyroid cancer with the shortest survival, once measured in months, into a treatable disease for the third of patients whose tumours carry a BRAF mutation.
ROAR, trial NCT02034110 sponsored by Novartis, is the phase 2 basket study whose anaplastic thyroid cancer cohort turned the thyroid cancer with the shortest survival, once measured in months, into a treatable disease for the roughly third of patients whose tumours carry a BRAF V600E mutation. In 36 patients treated with dabrafenib plus trametinib the objective response rate was 56 percent, with survival far beyond historical expectations in the 2022 update in Annals of Oncology, leading to FDA approval in May 2018 as the first targeted therapy for the disease; neoadjuvant use now enables surgery in previously unresectable tumours. OnCo links it to thyroid cancer, BRAF as a target, the dabrafenib plus trametinib record, MD Anderson, Maria E. Cabanillas and the pairing of BRAF and MEK inhibition before surgery. Whether adding PD-1 blockade should become standard is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Basket trial, Single-arm trial, Objective response rate (ORR), Basket, umbrella, and platform trials.
Shares Basket trial, Single-arm trial, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Dabrafenib + trametinib, Basket, umbrella, and platform trials, BRAF, Novartis.
Shares Dabrafenib + trametinib, BRAF, Novartis, Small-molecule kinase inhibitors.
Shares Dabrafenib + trametinib, BRAF, Novartis, Small-molecule kinase inhibitors.
Shares Novartis, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Basket trial, Single-arm trial, Basket, umbrella, and platform trials.